Whole body positron emission tomography in follow-up of high risk melanoma

References

• URL:, http://www.cancerregistry.fi/eng/statistics/.
   Google Scholar
• Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635–48
   PubMed Web of Science ®Google Scholar
• Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 17: 197–8
   PubMed Web of Science ®Google Scholar
• Ludwig V, Komori T, Kolb D, Martin WH, Sandler MP, Delbeke D. Cerebral lesions incidentally detected on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography images of patients evaluated for body malignancies. Mol Imaging Biol 2002; 4: 359–62
   PubMedGoogle Scholar
• Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104: 570–9
   PubMed Web of Science ®Google Scholar
• Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003; 29: 662–4
   PubMed Web of Science ®Google Scholar
• Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77: 237–42
   PubMed Web of Science ®Google Scholar
• Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002; 7: 271–8
   PubMed Web of Science ®Google Scholar
• Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19: 2674–8
   PubMed Web of Science ®Google Scholar
• Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol 1999; 140: 249–54
   PubMed Web of Science ®Google Scholar
• Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993; 91: 94–8
   PubMed Web of Science ®Google Scholar
• Horn J, Lock-Andersen J, Sjøstrand H, Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006; 33: 887–92
   PubMed Web of Science ®Google Scholar
• Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999; 86: 2252–8
   PubMed Web of Science ®Google Scholar
• Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325–9
   PubMed Web of Science ®Google Scholar
• Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003; 21: 520–9
   PubMed Web of Science ®Google Scholar
• Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345–53
   PubMed Web of Science ®Google Scholar
• Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999; 71: 209–13
   PubMed Web of Science ®Google Scholar
• Essner, R, Lee, JH, Wanek, LA, Itakura, H, Morton, DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004;139:961–6; Discussion 966–7.
   PubMedGoogle Scholar
• Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N, et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002; 55: 46–54
   PubMedGoogle Scholar
• Australian Cancer Network:. Guidelines for the management of cutaneous melanoma. Stone Press, Sydney 1997
   Google Scholar
• Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: Impact on surgical decision making. Clin Nucl Med 2003; 28: 961–5
   PubMed Web of Science ®Google Scholar
• Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019–25
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2005; 93: 243–9
   Web of Science ®Google Scholar
• Koskivuo I, Suominen E, Niinikoski J, Talve L. Sentinel node metastasectomy in thin <or = 1-mm melanoma. Langenbecks Arch Surg 2005; 390: 403–7
   PubMed Web of Science ®Google Scholar
• Blocklet D, Donckier V, Vereecken P, Van Geertruyden J, Laporte M, Goldman S. Nondetection of sentinel lymph node with lymphoscintigraphy as a result of massive malignant invasion shown by positron emission tomography. Clin Nucl Med 2001; 26: 1013–5
   PubMed Web of Science ®Google Scholar
• Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664–71
   PubMed Web of Science ®Google Scholar
• Holder, WD, Jr, White, RL, Jr, Zuger, JH, Easton, EJ, Jr, Greene, FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764–9; Discussion 769–71.
   PubMed Web of Science ®Google Scholar
• Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, et al. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006; 13: 525–32
   PubMed Web of Science ®Google Scholar